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Abstract
Background
Confusion between look-alike and sound-alike (LASA) medication names (such as
mercaptamine and mercaptopurine) accounts for up to one in four medication errors, threat-
ening patient safety. Error reduction strategies include computerized physician order
entry interventions, and ‘Tall Man’ lettering. The purpose of this study is to explore the medi-
cation name designation process, to elucidate properties that may prime the risk of
confusion.
Methods and Findings
We analysed the formal and semantic properties of 7,987 International Non-proprietary
Names (INNs), in relation to naming guidelines of the World Health Organization (WHO)
INN programme, and have identified potential for errors. We explored: their linguistic proper-
ties, the underlying taxonomy of stems to indicate pharmacological interrelationships, and
similarities between INNs. We used Microsoft Excel for analysis, including calculation of
Levenshtein edit distance (LED). Compliance with WHO naming guidelines was inconsis-
tent. Since the 1970s there has been a trend towards compliance in formal properties, such
as word length, but longer names published in the 1950s and 1960s are still in use. The
stems used to show pharmacological interrelationships are not spelled consistently and the
guidelines do not impose an unequivocal order on them, making the meanings of INNs diffi-
cult to understand. Pairs of INNs sharing a stem (appropriately or not) often have high levels
of similarity (<5 LED), and thus have greater potential for confusion.
Conclusions
We have revealed a tension between WHO guidelines stipulating use of stems to denote
meaning, and the aim of reducing similarities in nomenclature. To mitigate this tension and
reduce the risk of confusion, the stem system should be made clear and well ordered, so as
to avoid compounding the risk of confusion at the clinical level. The interplay between the
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different WHO INN naming principles should be further examined, to better understand their
implications for the problem of LASA errors.
Background
Medication errors make up a high proportion of all events related to patient safety [1,2], and
are particularly common in intensive care, paediatrics/neonatology, care of the elderly, anaes-
thetics, and obstetrics [2,3]. Some medication errors will result in overdose, adverse drug reac-
tions, or under-treatment, and cause serious harm to patients [4–6]. As more medications
enter the market, with greater variation in routes of administration, this problem is becoming
increasingly complex [7].
Errors can occur when medications have similar-looking or similar-sounding names; these
are called look-alike, sound-alike (LASA) errors. LASA errors are estimated to account for
around one in every four medication errors in the USA [8], and they can occur during prescrib-
ing, transcribing, dispensing, and administration (examples in Table 1). Studies of United
States Adopted Names (USANs), many of which take the form of International Nonpropri-
etary Names (INNs), have shown that the prescribing frequency of certain medications may
prime the risk of LASA errors, and certain pre-approval strategies have been recommended,
such as computerized searches, expert judgement, and psycholinguistic testing [9]. Most litera-
ture on LASA errors, involving confusion between both brand and generic names (brand-
brand, generic-brand, and generic-generic), deals with mitigation strategies and regulatory
obligations, such as ‘Tall Man’ lettering on packaging to highlight distinguishing characters
(for example, lamoTRIGine/lamiVUDine) and technological solutions, such as alerts built into
prescription software and automated reporting systems [4,8,10–12].
To date, very few studies have looked at the formal properties of generic names and their
relation to LASA errors, and these concerned USANs, not INNs [17]. To our knowledge, this is
the first study to contextualize the formal properties of INNs within the WHO naming guide-
lines, and the first to look at semantic properties, by exploring the underlying conceptual sys-
tem that groups names according to their pharmacology. Since INNs are the global
pharmaceutical nomenclature from which national nomenclature systems are derived, study of
the formal characteristics of INNs is of real importance to those interested in medications man-
agement, LASA errors, and patient safety. Identification of the factors that should be consid-
ered in naming new medications is important for products coming to market.
Table 1. Examples of LASA errors.
Reference Medications involved
(International Nonproprietary
Name)
Type of incident Clinical outcome
[13] mercaptopurine (A);
mercaptamine (B)
A prescribed instead of B by GP Infant initially presented with nephropathic cystinosis. After one
month on the wrong medication, the infant developed
pancytopenia, but made a full recovery.
[14] hydromorphone (C); morphine (D) C administered instead of D by
nurse
The patient (an elderly man) was discharged and suffered a fatal
respiratory arrest on his way home.
[15] gentamicin (E); clindamycin (F) E administered instead of F Not speciﬁed, but labelled ‘low harm’.
[16] cisatracurium (G); vecuronium (H) G dispensed instead of H by
pharmacy technician and was
administered
The patient was a 30+1 week old neonate. The error was
realized immediately, and no changes to vital signs were
observed.
doi:10.1371/journal.pone.0145431.t001
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1.1 International Nonproprietary Names
International Nonproprietary Names (INNs) constitute a nomenclature of over 8,000 generic
names for pharmaceutical substances. Some examples are given in Table 2. They are designated
by the World Health Organization (WHO) and formally placed in the public domain to pro-
mote consistency in global communication between manufacturers, clinicians, prescribers, and
patients. INNs are published in the six official languages of the United Nations and Latin, and
are used by default as generic names in major national and regional pharmacopoeias, such as
the British Pharmacopoeia and the European Pharmacopoeia [18]. Given their international
status, the name designation process in place must encompass a wider conceptual system than
that of regional naming councils, and naming guidelines must be robust and applied
stringently.
INNs are designated in accordance with a set of naming guidelines, which give guidance on
formal properties, such as spelling, phonology, hyphenation, and word length, and semantic
properties, such as the use of stems to indicate pharmacological relationships between sub-
stances. Here we present an analysis of the formal and semantic properties of INNs, based on
the naming guidelines of the WHO INN program, and discuss its clinical significance.
INNs are designated and promoted for international use and are restricted by a set of guide-
lines (‘principles’). Principles 1 and 2 are marked as ‘guiding principles’, and the WHO stipu-
lates that “these primary principles are to be implemented by using the following secondary
principles” [20]. The WHO naming principles in designating INNs that we explore here are
provided in Table 3, and the full list of principles in S1 Table:WHO naming principles for desig-
nation of INNs. The other five principles were not looked at, since they pertained to particular
classes (such as acids and salts), the regulation of INN designation, or purely phonetic aspects.
Motivation behind these selected principles falls into four categories:
1. Usability: how easily can the name be used in the four modalities of language: reading, writ-
ing, listening, and speaking? Is the name memorable, and can it be printed on packaging?
2. Taxonomy: does the name indicate its position in the conceptual system, and interrelation-
ships? This is a two-fold condition: there must be a robust and consistent conceptual system,
and the formal properties of the names should be exploited to map on to the underlying
conceptual system.
3. Clarity: how liable is the name to be confused with other names, both in the same system
and in other systems?
4. International use: does the name adhere to the phonotactics of all languages in which it is
used, and can it be easily transliterated into other languages with different alphabets or
Table 2. Examples of International Nonproprietary Names (INNs).
Year
recommended
INN Examples of current therapeutic indication(s) [19]
1955 chloramphenicol Topical treatment of acute bacterial conjunctivitis
1965 betamethasone Topical treatment of various dermatoses, including atopic dermatitis, psoriasis, and discoid lupus
erythematosus
1975 levonorgestrel 72-hour emergency contraception
1985 mifepristone Medical termination of developing intra-uterine pregnancy
1995 atorvastatin Treatment of hypercholesterolaemia and prevention of cardiovascular disease
2005 golimumab Treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis
doi:10.1371/journal.pone.0145431.t002
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writing systems? (As illustrated by montelukast in Fig 1, INNs are published in Latin,
English, Spanish, French, Russian, Chinese, and Arabic.).
Here we address the overarching research question: In relation to the WHO principles of
INN designation, are there any threats to interpretation or translation in the form of:
1. Isolated numbers, isolated characters, or hyphens present in INNs (principle 6)
2. Prohibited graphs and digraphs present in INNs (principle 7)
3. Word length statistics (principle 1c)
4. Use of stems to indicate pharmacological relationships (principle 2a)
5. Patterns of similarity between INNs (principle 1d)
Table 3. SelectedWHO naming principles for designation of INNs (taken from [20]; sub-categorized
here using square brackets).
Principle
1
International Nonproprietary Names (INNs) should be distinctive in [a] sound and [b] spelling.
[c] They should not be inconveniently long and [d] should not be liable to confusion with
names in common use.
Principle
2
[a] The INN for a substance belonging to a group of pharmacologically related substances
should, where appropriate, show this relationship. [b] Names that are likely to convey to a
patient an anatomical, physiological, pathological, or therapeutic suggestion should be
avoided.
Principle
6
The use of an isolated letter or number should be avoided; hyphenated construction is also
undesirable.
Principle
7
To facilitate the translation and pronunciation of INNs, "f" should be used instead of "ph", "t"
instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and
"k" should be avoided. When devising an INN it is important to be aware of possible language
problems. Since the name is used worldwide, not only should certain letters be avoided, but
experts need to be aware of unsuitable connotations in the major languages spoken in the
world.
doi:10.1371/journal.pone.0145431.t003
Fig 1. Montelukast in translated forms.
doi:10.1371/journal.pone.0145431.g001
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Methods
The present analysis is concerned with the formal and semantic properties of International
Nonproprietary Names, and was undertaken within the framework of naming guidelines
(‘principles’) set out by the WHO [20,21]. In linguistics, the descriptors formal and semantic
are often dichotomized to compare, respectively, the written or phonetic form of a word and its
underlying conceptual meaning(s). These are inseparable facets of natural language, but the
distinction is useful for analytical purposes [22].
As a starting point for the analysis, all INNs (n = 7,987) published in Recommended Lists
from 1952 (when the INN program began) to August 2012 were digitized into an Excel spread-
sheet. They were cross-verified on WHOMedNet. Two Excel databases were created, the first
containing all single-word INNs (n = 7,111) and the second containing multi-word INNs
(n = 876). The multi-word database was used for analysis under Question 1 concerning isolated
numbers, characters, or hyphens. Any names containing a space or a non-alphanumeric char-
acter (such as a hyphen) were included in the multi-word database. The single-word database
was used for analysis of Questions 2–5. Fig 2 summarizes the sampling process.
The use of stems (Question 4) was explored qualitatively in a randomly selected 1% segment
(using the RAND function in Excel) of the single-word database (n = 71), as it was decided that
for this question depth of analysis was preferable over breadth. The WHO Stembook [20] was
used to verify that each INN in the 1% segment of the single-word database (n = 71) incorpo-
rated the correct stem(s). The 1% random sample was used as a starting point for our analysis,
which explored the complete stem taxa of each stem and sub-stem contained in the 43 names.
For Question 5, concerning patterns of similarity between INNs, pairwise similarity was
measured between the 1% random sample (71 INNs) against the entire single-word database
(7,111 INNs). This was to limit processing power requirements, as measuring pairwise similar-
ity between every name would result in over 50 million calculations, rather than 504,881 using
a 1% sample, and manual inspection was needed for each pair to ascertain stem or sub-stem
commonalities. The measurement of similarity used was Levenshtein edit distance (LED),
which accounts for differences in word length [23] and is used in spell checking and predictive
text software. It computes the number of insertions, deletions, or substitutions necessary to
transform one string into another. For example, to transform book into back, o would be
Fig 2. The sampling process.
doi:10.1371/journal.pone.0145431.g002
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substituted for a, and the next o would be substituted for c, and the LED is 2. The LED is sensi-
tive to differences in word length; for example, to transform mercaptopurine into mercapta-
mine, a replaces o,m replaces p, and u and r are deleted, so the LED is 4. Since the function’s
algorithm is processed linearly through the characters in each string, matching sequences will
decrease the LED.
For ease of reference, this paper will refer to hyperonyms as stems and hyponyms as sub-
stems. Stems are underlined for brevity.
Results
1. Are isolated numbers, isolated characters, or hyphens present in
INNs? (principle 6)
The presence of isolated characters in an INN can endanger its interpretation. In word pro-
cessed documents, the name may be split over two lines and the isolated character may be mis-
interpreted as a page number or footnote marker. In handwriting, a single letter is more easily
misinterpreted than a word, because the reader cannot rely on other characters for context. Iso-
lated numbers may be mistaken for part of the dosage instructions and result in wrong dosing.
In the multiword INNs database, seven INNs contained a hyphen, six of which hyphenate a
Greek letter and alphanumeric code, e.g. peginterferon lambda-1a. There are no instances of a
single isolated number or character, although INNs with a second alphanumeric word, such as
ioflubenzamide 131I, create a risk of misinterpretation due to similarity between an upper-case
eye, a lower case el, and the number one, even when printed, which all look the same in, for
example, the Bauhaus 93 and Gill Sans MT fonts [24].
2. Are prohibited graphs and digraphs present in INNs? (principle 7)
Principle 7 is in place to facilitate the translation and correct pronunciation of INNs. By pro-
hibiting graphs and digraphs such as<h> and<th>, which correspond to phonemes not pre-
dictably used in other languages, the principle facilitates translation of the name from Latin
into the six official languages of the WHO (English, Spanish, French, Russian, Chinese, and
Arabic), from which generic names in other languages are derived. There are wide variations in
the pronunciation and writing systems in the world’s languages, so a simplification of English
phonology is necessary. Principle 7 also serves Principle 1a and 1b (names should be distinctive
in sound and spelling), by promoting the use of primary graphs with a one-to-one correspon-
dence with phonemes, such as<f> (not<ph>) for phoneme /f/, and<e> (not<ae> or
<oe>) for /e/. In this way, redundancy is avoided by using a single grapheme for each pho-
neme, and name length is reduced by one letter. INNs are therefore required to have an inter-
nal shallow orthography, i.e. one in which the correspondences between graphemes and
phonemes are close to one-to-one.
Principle 2, which is given priority by the WHO, stipulates that names must show pharma-
cological relationship, and thus there is a conflict between principles 2 and 7. Although<ph>,
<th>,<oe>,<y>,<h>, and<k> are prohibited, these (di)graphs are present in the list of
stems used to form INNs (e.g. -kacin, -methasone, -orphinol) and so inevitably will be used.
Furthermore, the Greek letter names theta and kappa are used to distinguish between similar
preparations, for example, the biosimilars epoetin alpha, beta, theta, and zeta. Given the lower
priority of Principle 7, it must be assumed that it should be adhered to unless the prohibited
(di)graph forms part of a recommended stem, such as in amikacin. The numbers of instances
of prohibited (di)graphs in INNs and stems are given in Table 4.
Patient Safety in International Drug Names
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Many instances of ‘h’ are attributable to those in<ph> and<th>, although it does appear
a further 171 times in the single-word INN database, either as an initial letter (e.g. hydrocorti-
sone) or with ‘chlor’ (e.g. chlorpromazine). In total, the prohibited (di)graphs occurred 1,677
times in 1,036 INNs. Some INNs contained more than one, such as phthalylsulfathiazole
(<ph>,<th>,<th>).
As shown by Fig 3 below, the majority of words containing prohibited (di)graphs were des-
ignated in the early stages of the INN programme, and few words continue to be designated.
For example, although -methasone is the recommended stem, recently designated INNs have
used the stem -metasone (e.g. dexamethasone in 1962, betamethasone in 1965, beclometasone
in 1970 and alclometasone in 1979).
3. Word length statistics (principle 1c)
Fig 4 shows the character count distribution in single-word INNs. The mean number of char-
acters across the entire dataset was 10.54, with a standard deviation of 1.73 characters. Both
median and mode were 10, and the interquartile range was 9 to 11.
There are nine outliers with more than 20 characters, and these were all recommended
before 1962. All nine contain at least one of the prohibited (di)graphs, which partly explains
their unusual length, and at least seven syllables: sulfachlorpyridazine (20 letters), succinylsul-
fathiazole (21), methyldihydromorphine (21), phthalylsulfathiazole (21), ethylmethylthiambu-
tene (22), phthalylsulfamethizole (22), sulfamethoxypyridazine (22), diiodohydroxyquinoline
(22), and phenoxymethylpenicillin (23). It is notable that these names more closely resemble
chemical names than do other INNs.
As shown in Fig 5, the average length of INNs dropped sharply in the 1970s, and has
remained steady since that time. The sudden drop coincided with the decreased use of (di)
graphs prohibited under principle 7 from the 11th list onwards.
Table 4. Instances of prohibited (di)graphs in INNs and stems.
ph th ae oe y h k Total
All INNs containing the (di)graph 157 257 1 8 577 561 106 1,677
Stems containing the (di)graph 4 1 0 1 4 5 14 29
doi:10.1371/journal.pone.0145431.t004
Fig 3. Number of prohibited (di)graphs contained in INNs published, by decade.
doi:10.1371/journal.pone.0145431.g003
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4. Are stems used to indicate pharmacological relationships? (principle
2a)
Pharmacological relationships between substances are demonstrated by the use of a common
stem [25] attached to a prefix, infix, suffix, or ‘freefix’. The use of stems and sub-stems creates a
taxonomic conceptual system for INNs, and allows users to exploit this systematicity to
improve retention, pronunciation, and recognition of the names. For example, montelukast
comprises the stem -ast, and the sub-stem–lukast. Users can recognize montelukast as a medi-
cation used to treat asthma, or more specifically, a leukotriene receptor antagonist, and they
can recognize that other names ending in–lukast have similar pharmacological actions to
montelukast.
Stems and sub-stems may be suffixes (at the end of the name, such as granisetron and palo-
nosetron), prefixes (at the beginning, such as artemether and arterolane), infixes (in the middle,
such as mifepristone and ulipristal) and freefixes (which can appear anywhere, such as nabi-
lone and nonabine). We encountered various types of taxonomy, which are outlined below.
INNs analysed in the 1% sample are given in S2 Table: Stems in 1% sample analysed semanti-
cally. Of the 71 INNs, 43 were listed in the WHO Stembook as “names in which the preferred
stem has been used in accordance with its definition”, and these were selected for analysis. The
remaining 28 were either missing from the Stembook, or listed as not containing the preferred
stem. For example, clortermine was listed under anorexics, which have the stem -orex, as an
INN in which the preferred stem has not been used. By extending this finding to the entire
Fig 4. Mean character count in 7,111 INNs.
doi:10.1371/journal.pone.0145431.g004
Fig 5. Mean character count of newly designated INNs by decade (This figure shows date of
publication: medications may have been in prior use, but not published as INNs.).
doi:10.1371/journal.pone.0145431.g005
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sample it may be inferred that up to 40%, or 3,150 names, do not contain the preferred or cor-
rect stem.
In the 43 INNs analysed semantically, 20 (47%) contained ‘lone’ stems, which have no taxo-
nomic relation to any other stems or sub-stems, such as -astine in clemastine, -azepide in pra-
nazepide, and -cromil in nedocromil. Others contained a stem belonging to a larger taxon,
such as montelukast in Table 5 (-ast: antiasthmatics or antiallergics, not acting primarily as
antihistaminics> -lukast: leukotriene receptor antagonist). The stem taxon contains a hypero-
nym (-ast), and multiple hyponyms or sub-stems (-lukast, -trodast).
An archetypal taxonomic system entails a clear tree hierarchy of concepts, based on hypero-
nyms and branching out to hyponyms. In the -ast taxon, and in many other INN taxa, the stem
is a suffix, attaching to the end of the name, and its sub-stem is formed by adding an infix. This
right-to-left display of taxonomy in montelukast is a predictable approach for the user, as they
can first categorize the substance under its main stem, antiasthmatics (-ast), and then sub-cate-
gorize it as a leukotriene receptor antagonist (-lukast).
The sample of 43 names also contained three names for monoclonal antibodies, formed by
the stem–mab (inolimomab, siplizumab and volociximab). As a newer branch of biochemistry,
they adhere to a much stricter nomenclature and a more systematic approach.
With the exception of the first medication in this class, muromonab-CD3, names for mono-
clonal antibodies comprise a random prefix, followed by two infixes and a stem referring in a
specified order to (a) the target class or disease class; (b) the source class on which the immuno-
globulin sequence is based; and (c) the hyperonym -mab [19]. There are currently eight infixes
to denote the source class and nine infixes to denote the target class. These may be combined
freely with each other but the order in which they appear in the word is fixed. As an example,
trastuzumab, which is a humanized monoclonal antibody directed against human epidermal
growth factor receptor type 2 (HER2), can be decomposed as tras-tu—zu—mab, in which -tu-
indicates that it targets tumour cells, and -zu- indicates that it is humanized (derived from a
non-human antibody, which is then engineered to be more homologous with human antibod-
ies). This is not an example of a three-tiered taxonomy, but rather two mutually independent
parameters of classification under a single hyperonym, as shown in Table 6.
However, there is no simple rule governing the position of stems and sub-stems in INNs.
There are many other ways in which stems are ordered in the name, because stems and sub-
stems may be prefixes, suffixes, infixes, or freefixes. The antiviral taxon, with hyperonymic
stem vir, is below in Table 7. Vir is a freefix, and can appear anywhere in the name. Sub-stems
of vir, including -viroc and -ciclovir, show that vir may be used as either a suffix or an infix,
and so it is difficult for a user to immediately categorize a name under its hyperonym as an
antiviral. A user may mistakenly categorize maraviroc under the stem -oc, which does not
Table 5. —ast stem taxon.
sub-stem
(hyponym)
stem
(hyperonym)
Mode of action Example
INN
Therapeutic indication
(without sub-
stem)
-ast antiasthmatics or antiallergics, not acting
primarily as antihistaminics
zaprinast A selective PDE inhibitor, precursor to PDE-5
inhibitors such as sildenaﬁl (Viagra) [26]
-lukast leukotriene receptor antagonists montelukast Treatment for reversible bronchoconstriction [19]
-milast phosphodiesterase type IV (PDE IV)
inhibitors
cilomilast Treatment for chronic obstructive airways disease
and psoriasis [19]
-trodast thromboxane A-2 receptor antagonists,
antiasthmatics
seratrodast Long-term management of asthma [27]
-zolast leukotriene biosynthesis inhibitors quazolast Mediator release inhibitor [28]
doi:10.1371/journal.pone.0145431.t005
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exist. Other pharmacologically unrelated medications that happen to include the word part vir,
such as virginiamycin and viridofulvin, may be misinterpreted as antivirals. In two other
names in the sample, the sub-stem is a suffix and thus the name cannot be immediately recog-
nized by its stem (such as: micinicate, with infix stem -nic(o)-; balaglitazone, with freefix stem
gli).
In many cases the orthographic form, instead of being exploited to facilitate interpretation,
actually obfuscates the semantics of the names. While pharmacological relationship must be
shown by using a common stem, some stems are distinguishable by only a single letter, such as
-fenin (diagnostic aids; (phenylcarbamoyl)methyl iminodiacetic acid derivatives, e.g. lidofenin
Table 6. —mab stem taxon.
sub-stem A (target) sub-stem B (source) stem Deﬁnition Example INNs
-mab Monoclonal antibody
-a- rat Not yet designated
-axo- rat/mouse catumaxomab
-e- hamster Not yet designated
-i- primate Not yet designated
-o- mouse solitomab
-u- human namilumab
-xi- chimeric pagibaximab
-xizu- chimeric/humanized otelixizumab
-zu- humanised natalizumab
-b(a)- bacterial teﬁbazumab
-c(i)- cardiovascular volociximab
-f(u)- fungal Not yet designated
-k(i)- interleukin lebrikizumab
-l(i)- immunomodulating inﬂiximab
-n(e)- neural atinumab
-s(o)- bone romosozumab
-tox(a)- toxin urtoxazumab
doi:10.1371/journal.pone.0145431.t006
Table 7. —vir stem taxon.
Sub-
stem
Stem Mode of action Example
INN
Therapeutic indication
vir Antivirals efavirenz Antiretroviral combination therapy in treatment of HIV-1 [19]
-amivir Neuraminidase inhibitors zanamivir Treatment of inﬂuenza [19]
-asvir Antivirals, hepatitis C virus (HCV) NS5A inhibitors daclatasvir Combination therapy for chronic hepatitis C [19]
-buvir RNA polymerase (NS5B) inhibitors dasabuvir Combination therapy for chronic hepatitis C [19]
-cavir Carbocyclic nucleosides abacavir Antiretroviral combination therapy in treatment of HIV [19]
-ciclovir Bicyclic heterocycle compounds valaciclovir Treatment of herpes zoster and ophthalmic zoster [19]
-fovir Phosphonic acid derivatives adefovir Treatment of chronic hepatitis B [19]
-gosivir Glucoside inhibitors celgosivir Potential treatment of dengue (DENV) virus [29]
-navir HIV protease inhibitors saquinavir Treatment of HIV-1 infected adults [19]
-previr Hepatitis Virus C (HVC) protease inhibitors telaprevir Treatment of genotype 1 chronic hepatitis C [19]
-virine Non-nucleoside Reverse Transcriptase Inhibitors
(NNRTI)
etravirine Treatment of HIV-1 in antiretroviral-experienced adults and
children over 6 [19]
-viroc CCR5 (Chemokine CC motif receptor 5) receptor
antagonists
maraviroc Treatment of detectable CCR5-tropic HIV-1 [19]
doi:10.1371/journal.pone.0145431.t007
Patient Safety in International Drug Names
PLOSONE | DOI:10.1371/journal.pone.0145431 December 23, 2015 10 / 16
and disofenin) and -fenine (analgesics, glafenine derivatives, e.g. florifenine and glafenine) and
many sub-stems in the -mab taxon comprise a single letter (cf. Table 6). In other cases, varia-
tion in the spelling of a stem (allomorphy) does not indicate a change in meaning (such as
indoprofen and diprofene, or setiptiline and noxiptiline).
The use of -ine as the ending of INNs (the most frequent ending, 1502 of 7,111 names in the
database) can falsely suggest a pharmacological relationship: for example, riodipine in the sam-
ple contains the stem -dipine (calcium channel blockers, 1,4-dihydropyridine derivatives), but
could be mistakenly interpreted under -pine (tricyclic compounds). Homophonic yet distinct
stems can also be misleading, such as -micin (gentamicin and netilmicin) and -mycin (erythro-
mycin and kanamycin), denoting antibacterials. This example also reveals inconsistencies in
the semantic motivation of stems. Here, the stem distinguishes the genus from which it is
derived, -micins fromMicromonospora and -mycins from Streptomyces, and not the pharma-
cological group, thereby blurring the boundaries between meanings of names containing these
stems.
As in the INNs for monoclonal antibodies, meaning may depend on the order of stem con-
catenation. For example, when -fos is used as a suffix, it is a hyperonym denoting “insecticides,
anthelminthics, pesticides etc., phosphorus derivatives”, e.g. uredofos, but when it appears as
an infix or a prefix, it is the hyponym (sub-stem) denoting “various pharmacological categories
belonging to fos, other than those above”, e.g. benfosformin [19]. In other cases, position in the
word does not indicate semantic difference, such as grel and vir, which have the same meaning
regardless of whether they are used as an infix or a suffix.
5. Are there patterns of similarity between INNs? (principle 1d)
Of 504,881 total pairwise similarity measures, 1,463 had a Levenshtein edit distance of between
1 and 4, i.e. no more than 4 characters or deletions distinguished the names. 33% (478 pairs) of
these shared a stem, and 88 (6%) also a sub-stem. These included prefixal stems such as arte- in
arterolane-arteflene, with an LED of 3, and the prefixes salazo- and sulfa- present together in
salazosulfadimidine-salazosulfamide, with an LED of 4. There were also pairs that had the
same final letters but did not share a stem indicating pharmacological relationship, such as
lagatide-giractide, in which the former has the stem -tide and the latter has the unrelated stem
-actide. Similarity statistics are given in Table 8. The table indicates the strong influence of
stems on similarity; the more similarity between two names, the more likely it is that they will
share a stem and/or a sub-stem.
The sample group contained four monoclonal antibody substances, represented by the
-mab stem family (icrumab, inolimomab, siplizumab and volociximab). Of the pairs with an
LED of<5, names for monoclonal antibodies occurred only in pairs, and did not display a
high degree of similarity with names with other stems. Pairs of monoclonal antibodies
Table 8. Similarity statistics.
Levenshtein Edit
Distance
Frequency Examples Percentage sharing a
stem
Percentage sharing both a stem and a
sub-stem
1 2 alverine-salverine; amezepine-mezepine 100% 0%
2 19 peplomycin-peliomycin; clortermine-
clormercaine
84.2% 26.3%
3 240 inolimomab-solitomab; pelubiprofen-
ﬂurbiprofen
62.9% 13.3%
4 1202 pibutidine-sufotidine; meclofenoxate-
metofenazate
25.7% 4.2%
doi:10.1371/journal.pone.0145431.t008
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presented a high proportion of all stem-based similarities (3 with LED = 2; 27 with LED = 3; 58
with LED = 4; total 88). For example, siplizumab scored an LED of 2 with both ruplizumab and
teplizumab, as they are only distinguishable by the first two letters. They share the stem -mab,
and both sub-stems -zu- and -li-. In words such as these, when seven letters are predetermined
by the norms of the designation process, the random prefix is responsible for the essential role
of distinguishing the name from its co-hyponyms.
Discussion
TheWHO naming principles considered in this paper have not been strictly observed. Only
the first two are prioritized, and these relate to the fourth and fifth objectives in this paper.
There is a clear trend towards stricter compliance with WHO principles after 1960, as most of
the extemely long names (20 characters or more) or those with prohibited (di)graphs were des-
ignated in the 1950s. These earlier INNs are still in use, and it is difficult to amend names after
publication in a recommended list in the public domain. However, we unearthed a more perva-
sive and important problem: the inherent tension between using common stems to indicate
pharmacological meaning and minimizing similarity in nomenclature to reduce confusion (see
4.2).
Another problem is that not all the principles are delimited and quantifiable, meaning they
are difficult to follow and almost impossible to regulate. For example, principle 1 (“Interna-
tional Nonproprietary Names (INNs) should be distinctive in sound and spelling. They should
not be inconveniently long and should not be liable to confusion with names in common use”)
[19] does not provide quantifiable criteria, such as a character limit, or a maximum degree of
similarity.
4.1 Formal Properties of Medication Names
In general, medication name designation complied with the WHO principles relating to formal
properties of nomenclature.
Some INNs contained hyphens, but no isolated letters and numbers were found. 1,677
INNs contain prohibited (di)graphs such as<ph> rather than<f>. Words without a one-to-
one grapheme-phoneme correspondence, such as thorough (eight graphs, four phonemes–/
θ er e/), take longer to be recognized in reading. Words containing graphs (letters) without
direct correspondence to their phonemes have been found to take longer to be recognized in
reading [30]. For example, fooph (3 phonemes and 5 graphs) will take longer to recognize
than fruls (5 phonemes and 5 graphs), because the reader first interprets the<p> in fooph
as the phoneme /p/, but then on meeting<h> is forced to reinterpret as the phoneme /f/. Rec-
ognition time is further increased when non-correspondences occur earlier in the word, as the
reader would not be able to infer meaning from the context of earlier letters. When analysed
into single graphs, the digraphs<ph>,<th>,<ae>, and<oe> do not have direct correspon-
dence with the primary phonemes of each graph and thus may increase recognition time and
reduce usability.
Word lengths of INNs are relatively stable diachronically, with an overall mean character
count of 10.54, but there are a few INNs with more than 20 characters. Long INNs, such as
phenoxymethylpenicillin (23 characters), are problematic to fit on packaging; the NPSA in the
UK, for example, has recommended a minimum font size of 16 points for the generic name
[31]. Long INNs risk being hyphenated and running to multiple lines when printed, reducing
legibility and increasing the risk of misunderstanding or confusion with other names. Recogni-
tion time will be increased by high character count, low frequency of the words and perceived
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‘nonwords’ [32,33], and this effect may be magnified by variation in the prescribing frequency
of INNs [34].
4.2 Potential for LASA errors
We have identified a tension between WHO principles stipulating the use of stems to indicate
pharmacological relationships and those aiming to reduce similarity in nomenclature.
If our numbers are representative of the totality of drug names, some soft inferences can be
made. Regarding use of stems (question 4), 23 out of 43 names displayed no problems in form
or taxonomy. The remaining 20 (47%) presented at least one problem, such as unpredictable
ordering of stems and sub-stems, variation in spelling (allomorphy), homophony, and similar-
looking but unrelated stems. By extension, we might estimate that 3,308 INNs in the total sam-
ple may be problematic. Secondly, 15 of 71 names (21%) are distinguishable from another
name by only one or two letters (LED is< = 2). By extension, we might estimate that 1,502
INNs in the total sample may share this degree of similarity with at least one other name.
Although these numbers are conjectural, as the degree of overlap to the total target lexicon
is uncertain, results from analysis of a 1% sample in fact pertain to a larger proportion of the
entire sample. We compared the 1% sample of INNs against 100% for pairwise similarity and
found that those sharing a stem are more likely to display a high degree of orthographic simi-
larity, a finding that can be extended to the other 99% of INNs in the sample. Similarly, our
analysis of the use of stems investigated over thirty stem taxa in depth and so is relevant to all
names containing stems from those taxa in the entire sample.
4.2.1 Stems indicating pharmacological relationships. There is no single way for a user
to predict meaning from an INN, although we found consistency within some taxa, e.g. mono-
clonal antibodies and antivirals. In some cases, a single letter will be used to distinguish
between unrelated pharmacological groups, whereas in other cases there is simply wide spelling
variation that does not contribute to meaning. The burden on users is high: they need to under-
stand the meanings of stems and the layout of the taxonomy, and also to learn when to ignore
spelling variations and when to take note of a single letter distinguishing meaning. They must
understand that meaning may be motivated at the supramorphemic level by the class of affix
and the concatenation of stems and sub-stems. Consequently, most clinicians make little use of
pharmacological nomenclature in routine practice, relying instead on the appearance and
sounds of whole words, memorized during experiential learning in clinical environments, and
on pharmaceutical company presentations, and preferring to use simpler brand names, miti-
gating against the use of generic names.
4.2.2 Patterns of similarity between INNs. Pharmacologically related substances whose
names show their relationship by the use of a common stem, and those that are unrelated but
erroneously shared a stem, have a higher level of similarity and are thus more likely to be con-
fused, such as:
1. arterolane-arteflene (arte-: antimalarial agents, artemisinin related compounds);
2. salazosulfadimidine-salazosulfamide (sal-: analgesic anti-inflammatories; salazo-: phenyla-
zosalicyclic acid derivatives antibacterial) (sulfa-: anti-infectives, sulfonamides); and
3. siplizumab-teplizumab (-mab: monoclonal antibodies; -li- and -zu-: humanized, targeting
the immune system)
This suggests that the use of the stem system may actually increase the risk of confusion and
thus endanger patients. However, without it users of pharmaceutical names would need to
learn the meanings of all medicines by rote, without the benefit of common affixes. Thus, two
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primary objectives of the WHO—usability and taxonomy—are in competition with each other,
and this is compounded by a messy underlying taxonomy.
We found significant levels of similarity between pharmacologically related INNs. Hence,
we have identified dissonance between sub-principles 1d (mitigating the risk of confusion) and
2a (stipulating the display of pharmacological relationship). These sub-principles compete in
the pursuit of the primary goals, namely, reduction of the risk of confusion with other medica-
tion names and accurate perception of the meanings of INNs. This conflict can only be miti-
gated when the stem system is predictably structured, to avoid increasing the risk of confusion.
Limitations
We have looked at formal and semantic properties of International Nonproprietary Names
within a selection of the WHO naming principles. We have examined orthographic form, but
not phonetic form, and used only one similarity measurement method. We analysed only
INNs in English, but studies are underway adapting these methods to the analysis of translated
forms (for example, in Latin, Spanish, French, Russian, Chinese, and Arabic), and evaluating
their compliance with WHO naming principles [19]. Further work is needed to explore the
clinical implications of this work.
A small sample (1%) was necessary, owing to available resources of time and processing
power. We estimate that analysis of the complete corpus would require up to 1,500 person-
hours. Our analysis was also restricted to names considered acceptable by the WHO, as it was
beyond our scope to analyse drug names that do not conform to WHO guidelines.
Conclusions
INNs carry out different functions depending on the user, and so they must be understandable
at multiple levels. For patients and non-professionals they must be recognisable and
pronounceable, and simultaneously their meaning and pharmacological relationships with
other names must be understood by health professionals if medication errors are to be avoided.
The pharmaceutical nomenclature and its peripheral systems of nomenclature (such as
pathology, anatomy, nosology, etc.) are extensive and complex. It is inevitable that a taxonomy
developed over a number of decades will contain some broken links and general inconsisten-
cies, but these should not work to the detriment of the overall aim of the system.
Like two sides of a coin, the formal and semantic aspects of language are inextricably linked,
and it is impossible to speak of formal motivation without referring to semantic motivation.
Formal aspects of INNs are motivated by the semantics they represent, and while the formal
realisation of INNs is, at times, conducive to conveying their meaning, it can also misrepresent
meaning and increase the risk of confusion.
Findings on word length (Question 3) were closely aligned with a similar study on USANs
[17], and have highlighted certain (di)graphs that are prohibited but nevertheless still in use
(Question 2). Results for Questions 4 and 5, regarding the use of stems and similarity, have
exposed a tension in the INN nomenclature, and highlighted the need for further research into
the exact interplay between these naming principles and their implementation.
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